OXRA-L 5MG/5MG TABLETS | Dapagliflozin & Linagliptin Diabetes Guide
OXRA-L 5MG/5MG TABLETS contain Dapagliflozin 5mg and Linagliptin 5mg, a combination antidiabetic medicine prescribed for type 2 diabetes management by improving blood glucose control.
OXRA-L 5MG/5MG TABLETS
OXRA-L 5MG/5MG TABLETS (DAPAGLIFLOZIN 5MG + LINAGLIPTIN 5MG): Comprehensive Guide and Benefits
Introduction to OXRA-L 5MG/5MG TABLETS
OXRA-L 5MG/5MG: Dual-Action Type 2 Diabetes Medicine
OXRA-L 5MG/5MG TABLETS contain a combination of two oral antidiabetic medicines: Dapagliflozin 5mg and Linagliptin 5mg. It belongs to the SGLT2 inhibitor + DPP-4 inhibitor antidiabetic class and is prescribed for improving blood sugar control in adults with type 2 diabetes mellitus when combination therapy is required.
Dapagliflozin helps remove excess glucose through urine, while Linagliptin enhances the body’s natural incretin pathway to support glucose regulation. OXRA-L 5MG/5MG TABLETS are prescription-only medicines and should be used under the supervision of a qualified healthcare professional.
Key Benefits of OXRA-L 5MG/5MG TABLETS
Helps improve blood glucose control in adults with type 2 diabetes.
Combines two complementary glucose-lowering mechanisms.
Supports removal of excess glucose through the kidneys.
Helps improve insulin response after meals.
May help reduce the risk of diabetes-related complications when used as part of a complete diabetes management plan.
How OXRA-L 5MG/5MG TABLETS Works
OXRA-L contains two active ingredients:
1. Dapagliflozin 5MG
Dapagliflozin is an SGLT2 (Sodium-Glucose Cotransporter-2) inhibitor. It blocks glucose reabsorption in the kidneys, allowing excess glucose to be eliminated through urine, which helps lower blood sugar levels.
2. Linagliptin 5MG
Linagliptin is a DPP-4 (Dipeptidyl Peptidase-4) inhibitor. It increases incretin hormone activity, which helps regulate insulin release after meals and reduces excess glucose production.
Together, these medicines provide dual-action glucose control for patients requiring combination therapy.
Usage Instructions for OXRA-L 5MG/5MG TABLETS
Take OXRA-L 5MG/5MG TABLETS exactly as prescribed by your doctor.
Swallow the tablet whole with water.
Do not crush, chew, or break the tablet.
It may be taken with or without food.
Take it at the same time each day for consistent results.
Do not stop treatment without consulting your healthcare provider.
Medicinal Advantages of OXRA-L 5MG/5MG TABLETS
Provides effective combination therapy for type 2 diabetes management.
Helps lower elevated blood glucose levels.
Supports glucose elimination through kidney pathways.
Helps improve glucose regulation after meals.
Offers an oral treatment option for patients requiring more than one diabetes medicine.
Note: OXRA-L should be combined with appropriate diet, exercise, and regular medical monitoring for optimal diabetes management.
Off-Label Uses of OXRA-L 5MG/5MG TABLETS
The combination of Dapagliflozin and Linagliptin should only be considered for additional uses when evaluated by a specialist based on clinical evidence.
Possible specialist-guided applications may include:
Individualized metabolic disease management approaches.
Additional cardiovascular or kidney-related strategies where medically appropriate.
Disclaimer: Off-label use should only be undertaken under qualified medical supervision.
Expert Advice for Optimal Use
Monitor blood glucose levels regularly.
Maintain adequate hydration unless fluid restriction is advised.
Follow a balanced diet and exercise routine.
Inform your doctor before surgery or prolonged fasting.
Report symptoms of urinary infection, dehydration, or unusual weakness.
Avoid changing doses without medical advice.
Precautions
Kidney Function
Patients with kidney disease should inform their doctor before starting OXRA-L. Kidney function monitoring may be required because Dapagliflozin works through kidney glucose handling.
Blood Sugar Monitoring
The risk of low blood sugar may increase when OXRA-L is used with insulin or sulfonylurea medicines. Dose adjustments may be required.
Pregnancy & Breastfeeding
Consult a healthcare professional before using OXRA-L during pregnancy or breastfeeding.
Drug Interactions
Inform your doctor about all medicines, including:
Insulin or other antidiabetic medicines
Diuretics (water tablets)
Blood pressure medicines
Kidney-related medicines
Herbal supplements
Existing Medical Conditions
Tell your doctor if you have:
Kidney disease
Liver disease
Frequent urinary infections
Dehydration problems
History of pancreatitis
Diabetic ketoacidosis
Storage Instructions
Store below 30°C.
Keep tablets in the original blister packaging.
Protect from moisture and direct sunlight.
Keep away from children.
Do not use after the expiry date.
Frequently Asked Questions (FAQs)
Q: What is OXRA-L 5MG/5MG TABLETS used for?
A: OXRA-L 5MG/5MG TABLETS are used to improve blood sugar control in adults with type 2 diabetes when combination therapy is required.
Q: What are the active ingredients in OXRA-L 5MG/5MG?
A: The active ingredients are Dapagliflozin 5mg and Linagliptin 5mg.
Q: Is OXRA-L an insulin medicine?
A: No. OXRA-L does not contain insulin. It works by improving glucose regulation through kidney glucose removal and incretin pathway support.
Q: Can OXRA-L 5MG/5MG be taken without prescription?
A: No. OXRA-L is a prescription medicine and should be used only under medical supervision.
Q: What are common side effects of OXRA-L?
A: Possible side effects may include urinary tract infections, genital fungal infections, low blood sugar (especially with other diabetes medicines), dizziness, weakness, and increased urination.
Q: Does OXRA-L help with kidney protection?
A: Dapagliflozin-containing therapies may provide kidney-related benefits in certain eligible patients, but use depends on individual health status and medical evaluation.
Product Tags
OXRA-L 5MG/5MG TABLETS, Dapagliflozin 5mg Linagliptin 5mg, Dapagliflozin Linagliptin Tablet, SGLT2 Inhibitor, DPP-4 Inhibitor, Type 2 Diabetes Medicine, Antidiabetic Combination Tablet, Blood Sugar Control Medicine, Diabetes Management Tablet, Oral Diabetes Medication, Prescription Diabetes Medicine, Kidney Support Diabetes Therapy, Cardiometabolic Medicine, OXRA-L Tablet.
